Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?
Michael Drummond, Oriana Ciani, Giulia Fornaro, et al.
BMC Health Services Research (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 19

Showing 19 citing articles:

Clinical trials to gene therapy development and production in Brazil: a review
Jonas Alex Morales Saute, Virgínia Picanço‐Castro, Ana Carolina de Freitas Lopes, et al.
The Lancet Regional Health - Americas (2025) Vol. 43, pp. 100995-100995
Closed Access | Times Cited: 1
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study
Maria Caterina Cavallo, Marianna Cavazza, Francesca Bonifazi, et al.
BMC Health Services Research (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 7
Promoting Equitable and Affordable Patient Access to Safe and Effective Innovations in Donation and Transplantation of Substances of Human Origin and Derived Therapies
Natividad Cuende, Stefan G. Tullius, Ander Izeta, et al.
Transplantation (2024) Vol. 109, Iss. 1, pp. 36-47
Closed Access | Times Cited: 5
How can actuarial science contribute to the field of health technology assessment? An interdisciplinary perspective
Oscar Espinosa, Michael Drummond, Elise Russo, et al.
International Journal of Technology Assessment in Health Care (2025) Vol. 41, Iss. 1
Closed Access
Mixture and Non-mixture Cure Models for Health Technology Assessment: What You Need to Know
Nicholas Latimer, Mark J. Rutherford
PharmacoEconomics (2024)
Open Access | Times Cited: 3
CAR-T cell therapies: patient access and affordability solutions
Elisabete Gonçalves
Future Science OA (2025) Vol. 11, Iss. 1
Open Access
Alternative Payment Models for Innovative Medicines: A Framework for Effective Implementation
Frederick McElwee, Amanda Cole, Gomathi Kaliappan, et al.
Applied Health Economics and Health Policy (2025)
Open Access
A Systematic Review of Challenges and Opportunities in the Implementation of Managed Entry Agreements for Advanced Therapy Medicinal Products
Andrea Greco, Geert Frederix, Lotty Hooft, et al.
Clinical Therapeutics (2024)
Open Access | Times Cited: 3
Mapping Payment and Pricing Schemes for Health Innovation: Protocol of a Scoping Literature Review
Vittoria Ardito, Ludovico Cavallaro, Michael Drummond, et al.
PharmacoEconomics - Open (2024) Vol. 8, Iss. 5, pp. 765-772
Open Access | Times Cited: 2
Design and Features of Pricing and Payment Schemes for Health Technologies: A Scoping Review and a Proposal for a Flexible Need-Driven Classification
Vittoria Ardito, Oriana Ciani, Michael Drummond
PharmacoEconomics (2024)
Open Access | Times Cited: 2
Onasemnogene Abeparvovec Gene Therapy and Risdiplam for the Treatment of Spinal Muscular Atrophy in Thailand: A Cost-Utility Analysis
Sarayuth Khuntha, Juthamas Prawjaeng, Kunnatee Ponragdee, et al.
Applied Health Economics and Health Policy (2024)
Open Access | Times Cited: 1
Challenges in the Evaluation of Emerging Highly Specialised Technologies: Is There a Role for Living HTA?
Tracy Merlin, Jackie Street, Drew Carter, et al.
Applied Health Economics and Health Policy (2023) Vol. 21, Iss. 6, pp. 823-830
Open Access | Times Cited: 3
Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid
Antal Zemplényi, Jim Leonard, Michael J. DiStefano, et al.
PharmacoEconomics (2023) Vol. 42, Iss. 3, pp. 319-328
Open Access | Times Cited: 3
Estimating the Potential Benefits of Confirmatory Trials for Drugs with Accelerated Approval: A Comprehensive Value of Information Framework
Boshen Jiao
PharmacoEconomics (2023) Vol. 41, Iss. 12, pp. 1617-1627
Closed Access | Times Cited: 2
Surrogacy and the Valuation of ATMPs: Taking Our Place in the Evidence Generation/Assessment Continuum
D. Gladwell, Oriana Ciani, Adam Parnaby, et al.
PharmacoEconomics (2023) Vol. 42, Iss. 2, pp. 137-144
Closed Access | Times Cited: 2
Market Access Challenges and Solutions in Cell and Gene Therapy in The Netherlands
Rimma Velikanova, Sharon Wolters, Hinko S. Hofstra, et al.
Journal of Market Access & Health Policy (2024) Vol. 12, Iss. 3, pp. 181-198
Open Access
Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy Therapies
Ryan Fischer, Pat Furlong, Annie Kennedy, et al.
Journal of Multidisciplinary Healthcare (2024) Vol. Volume 17, pp. 4199-4212
Open Access
Advanced Therapy Medicinal Products: Availability, Access and Expenditure in Italy
Pia Rivetti di Val Cervo, Eva Alessi, Marilena Lastella, et al.
BioDrugs (2024) Vol. 38, Iss. 6, pp. 831-844
Open Access
Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy Therapies
Ryan Fischer, Pat Furlong, Annie Kennedy, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1

Scroll to top